PYGM and glycogen storage disease V: The isogenic iPSC model for McArdle disease (composed by the line MA1-B9 as isogenic control and the line MA1 as McArdle line harbouring the mutation c.148C>T; p.R50* in the PYGM gene) was employed to evaluate the action of two read-through compounds as possible therapy.